Drug Profile

ABP 160

Alternative Names: ABP-160

Latest Information Update: 30 Jun 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Abpro Therapeutics
Class Antineoplastics; Bispecific antibodies; Immunotherapies
Mechanism of Action CD47 antigen modulators; Programmed cell death-1 ligand-1 modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

30 Jun 2023 Early research is ongoing in USA (Abpro Therapeutics pipeline, June 2023)
28 Sep 2018 Early research in Cancer in USA (Parenteral) (Abpro Therapeutics, September 2018)
11 Apr 2018 Abpro Threpeutics has patents pending for certain bispecific antibodies in USA

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com